Innoplexus enters an academic collaboration with Regional Cancer Centre (RCC), Gwalior

Innoplexus enters an academic collaboration with Regional Cancer Centre (RCC), Gwalior

Innoplexus enters an academic collaboration with Regional Cancer Centre (RCC), Gwalior
Innoplexus will provide an academic license to doctors and researchers at RCC, Gwalior, under the association, allowing them free access to its cloud-based decision support platform, iPlexusTM.

Innoplexus, the technology and product development company focused on AI and advanced analytics, has announced a collaboration with Regional Cancer Centre (RCC), Gwalior. 

Innoplexus will provide an academic license to doctors and researchers at RCC, Gwalior, under the association, allowing them free access to its cloud-based decision support platform, iPlexusTM. 

With over 100+ terabytes of indexed scientific data available to them at their fingertips, researchers at RCC will be able to gain insights into the latest advancements in research and trials related to cancer and make swift, agile decisions pertinent to their R&D endeavours.

Dr. Gunjan Bhardwaj, Founder and Chairman, Innoplexus, said, "We are extremely delighted to announce our academic partnership with Regional Cancer Centre, Gwalior, which is in line with our vision to make access to insights real-time, comprehensive, and cost-effective.

"The need of the hour for medical research is to leverage machine learning, AI, and big data to generate continuous intelligence. This is what our recently launched iPlexusTM platform enables. We are confident that the partnership will streamline the discovery and analysis for researchers and doctors at RCC, Gwalior, and assist them in elevating their cancer-related research to another level."

Dr. B.R. Srivastava, Regional Cancer Centre, Gwalior, added, "Some of the most challenging issues facing research today are heavy data fragmentation and scattered availability of relevant information. This is something that iPlexusTM can solve with its innovative, tech-driven approach. 

"This technology has the potential to transform biomedical research by enabling swift access to relevant and credible information to researchers, allowing them to make agile decisions swiftly and effortlessly."

iPlexusTM has already been heralded as a game-changing development in the biomedical sector, and can benefit R&D and commercial teams associated with pharmaceutical companies, policymaking, clinicians, and research institutes.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Franchise india Insights
The Franchising World Magazine

For hassle-free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online

Newsletter Signup

Share your email address to get latest update from the industry